ZA200307901B - Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock. - Google Patents
Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock. Download PDFInfo
- Publication number
- ZA200307901B ZA200307901B ZA200307901A ZA200307901A ZA200307901B ZA 200307901 B ZA200307901 B ZA 200307901B ZA 200307901 A ZA200307901 A ZA 200307901A ZA 200307901 A ZA200307901 A ZA 200307901A ZA 200307901 B ZA200307901 B ZA 200307901B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- peptide
- treatment
- endotoxic shock
- sequence
- Prior art date
Links
- 206010040070 Septic Shock Diseases 0.000 title claims description 11
- 206010014824 Endotoxic shock Diseases 0.000 title claims description 10
- 230000002265 prevention Effects 0.000 title claims description 6
- 239000012634 fragment Substances 0.000 title claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- -1 amino, hydroxy Chemical group 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000004149 thio group Chemical group *S* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000762A ITMI20010762A1 (it) | 2001-04-10 | 2001-04-10 | Uso della proteina uk114 o di suoi frammenti per il trattamento e la prevenzione dello shock endotossico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307901B true ZA200307901B (en) | 2004-10-11 |
Family
ID=11447468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307901A ZA200307901B (en) | 2001-04-10 | 2003-10-09 | Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040180835A1 (sk) |
| EP (1) | EP1377308A1 (sk) |
| JP (1) | JP2004526762A (sk) |
| KR (1) | KR20040000423A (sk) |
| CN (1) | CN1501807A (sk) |
| BG (1) | BG108246A (sk) |
| BR (1) | BR0208793A (sk) |
| CA (1) | CA2443726A1 (sk) |
| CZ (1) | CZ20032744A3 (sk) |
| EE (1) | EE200300489A (sk) |
| HR (1) | HRP20030815A2 (sk) |
| HU (1) | HUP0303798A3 (sk) |
| IL (1) | IL158333A0 (sk) |
| IT (1) | ITMI20010762A1 (sk) |
| MX (1) | MXPA03009228A (sk) |
| NO (1) | NO20034723L (sk) |
| PL (1) | PL367764A1 (sk) |
| RU (1) | RU2003130226A (sk) |
| SK (1) | SK12582003A3 (sk) |
| WO (1) | WO2002083161A1 (sk) |
| YU (1) | YU80003A (sk) |
| ZA (1) | ZA200307901B (sk) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1244879B (it) * | 1990-12-11 | 1994-09-12 | Alberto Bartorelli | Estratti da tessuti animali, utili in terapia e in diagnostica. |
| IT1270618B (it) * | 1994-07-14 | 1997-05-07 | Zetesis Spa | Proteine ad attivita' antitumorale |
| IT1282608B1 (it) * | 1996-02-13 | 1998-03-31 | Zetesis Spa | Sequenza oligonocleotidica da fegato di capra |
| CA2266346A1 (en) * | 1996-09-18 | 1998-03-26 | Zetesis S.P.A. | Use of proteins as agents against autoimmune diseases |
| IT1290828B1 (it) * | 1997-03-25 | 1998-12-11 | Zetesis Spa | Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche |
| IT1298442B1 (it) * | 1998-02-24 | 2000-01-10 | Zetesis Spa | Composizioni orali a basso dosaggio di proteine citotossiche |
-
2001
- 2001-04-10 IT IT2001MI000762A patent/ITMI20010762A1/it unknown
-
2002
- 2002-04-09 EP EP02742881A patent/EP1377308A1/en not_active Withdrawn
- 2002-04-09 IL IL15833302A patent/IL158333A0/xx unknown
- 2002-04-09 CZ CZ20032744A patent/CZ20032744A3/cs unknown
- 2002-04-09 KR KR10-2003-7013252A patent/KR20040000423A/ko not_active Application Discontinuation
- 2002-04-09 CA CA002443726A patent/CA2443726A1/en not_active Abandoned
- 2002-04-09 SK SK1258-2003A patent/SK12582003A3/sk unknown
- 2002-04-09 PL PL02367764A patent/PL367764A1/xx not_active Application Discontinuation
- 2002-04-09 YU YU80003A patent/YU80003A/sh unknown
- 2002-04-09 CN CNA028079485A patent/CN1501807A/zh active Pending
- 2002-04-09 HU HU0303798A patent/HUP0303798A3/hu unknown
- 2002-04-09 MX MXPA03009228A patent/MXPA03009228A/es unknown
- 2002-04-09 EE EEP200300489A patent/EE200300489A/xx unknown
- 2002-04-09 JP JP2002580963A patent/JP2004526762A/ja active Pending
- 2002-04-09 BR BR0208793-6A patent/BR0208793A/pt not_active IP Right Cessation
- 2002-04-09 RU RU2003130226/15A patent/RU2003130226A/ru not_active Application Discontinuation
- 2002-04-09 US US10/474,379 patent/US20040180835A1/en not_active Abandoned
- 2002-04-09 WO PCT/EP2002/003933 patent/WO2002083161A1/en not_active Application Discontinuation
-
2003
- 2003-10-09 BG BG108246A patent/BG108246A/bg unknown
- 2003-10-09 ZA ZA200307901A patent/ZA200307901B/en unknown
- 2003-10-09 HR HR20030815A patent/HRP20030815A2/hr not_active Application Discontinuation
- 2003-10-22 NO NO20034723A patent/NO20034723L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040180835A1 (en) | 2004-09-16 |
| EP1377308A1 (en) | 2004-01-07 |
| EE200300489A (et) | 2003-12-15 |
| NO20034723D0 (no) | 2003-10-22 |
| CA2443726A1 (en) | 2002-10-24 |
| ITMI20010762A0 (it) | 2001-04-10 |
| ITMI20010762A1 (it) | 2002-10-10 |
| NO20034723L (no) | 2003-10-22 |
| WO2002083161A1 (en) | 2002-10-24 |
| HUP0303798A3 (en) | 2005-12-28 |
| BG108246A (bg) | 2005-04-30 |
| HUP0303798A2 (hu) | 2004-03-01 |
| HRP20030815A2 (en) | 2005-08-31 |
| IL158333A0 (en) | 2004-05-12 |
| KR20040000423A (ko) | 2004-01-03 |
| JP2004526762A (ja) | 2004-09-02 |
| MXPA03009228A (es) | 2004-03-16 |
| RU2003130226A (ru) | 2005-02-10 |
| PL367764A1 (en) | 2005-03-07 |
| YU80003A (sh) | 2006-05-25 |
| CZ20032744A3 (en) | 2004-05-12 |
| BR0208793A (pt) | 2004-03-09 |
| SK12582003A3 (sk) | 2004-03-02 |
| CN1501807A (zh) | 2004-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9844584B2 (en) | Composition for preventing or treating sepsis | |
| US8454967B2 (en) | Compositions and methods for modulating the immune system | |
| KR20010030563A (ko) | 인터페론 칸센서스 및 인터루킨-1 수용체 길항물질을 포함하는 다발성경화증을 치료하기 위한 제약학적 조성물 | |
| WO1995000166A1 (en) | Pharmaceutical compositions for stimulating reconstruction of hemopoietic microenvironment | |
| KR102001437B1 (ko) | 섬유증의 예방 또는 치료용 약학 조성물 | |
| US7468353B2 (en) | Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases | |
| CA2122596C (en) | Treatment of neurological conditions by an interleukin-1 inhibiting compound | |
| US9101593B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
| DE602004001509T2 (de) | Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung | |
| EP0403458B1 (en) | Novel polypeptides and their use | |
| ZA200307901B (en) | Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock. | |
| US20020072499A1 (en) | Treatment with small peptides to effect antifibrotic activity | |
| US20070032412A1 (en) | Use of Kahalalide Compounds for the Manufacture of a Medicament for the Treatment of Psoriasis | |
| AU2002338299A1 (en) | Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock | |
| JP4023863B2 (ja) | Ｉｌ−６を含む血清尿酸値低下剤 | |
| RU2721282C2 (ru) | Способ лечения рассеянного склероза (варианты) | |
| WO1998042366A1 (en) | The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf) | |
| CN108853483B (zh) | 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途 | |
| JPH09506115A (ja) | 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物 | |
| CN111574590B (zh) | 一种具有抗肿瘤功能的多肽及其应用 | |
| JPH09510688A (ja) | Ｃｘｃインタークリン分子のペプチド阻害剤 | |
| KR20220066825A (ko) | 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물 | |
| CN115364195A (zh) | Thiostrepton在制备预防和治疗硬皮病的药物中的应用 | |
| JPH07506587A (ja) | 単量体および二量体のペプチド，細胞防護剤としての利用および製造方法 | |
| CN118236470A (zh) | MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用 |